International Edition
Latest News
Health

Disabling Cellular Recycling Gene Boosts Yield of Hard-to-Make Drug Target Proteins

Cells modified to shut down their internal recycling systems produced significantly larger amounts of target membrane proteins for drug development, according to a study published in November 2026 in the journal Cell Systems. Researchers at KTH Royal Institute…

Disabling Cellular Recycling Gene Boosts Yield of Hard-to-Make Drug Target Proteins

Cells modified to shut down their internal recycling systems produced significantly larger amounts of target membrane proteins for drug development, according to a study published in November 2026 in the journal Cell Systems.

Researchers at KTH Royal Institute of Technology and AstraZeneca disabled the pathway that human cells normally use to recycle proteins and organelles, addressing a persistent bottleneck in pharmaceutical research. Approximately 60 percent of approved medicines target membrane proteins, but manufacturing them in useful quantities remains difficult.

Protein Yield Increases After ULK1 Knockout
Target Protein Yield Increase
GIPR 30 percent
GPR75 80 percent
P2X3 100 percent

Instead of trying to boost cellular production machinery, the research team disabled the gene ULK1, which initiates autophagy, said Johan Rockberg, professor of directed evolution at KTH.

“We expected cells without working autophagy to struggle,” Rockberg says. “Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain.”

To analyze how human cells coped with the removal of autophagy, Alice Karlsson, a doctoral student in biotechnology at KTH, examined intracellular activity.

“The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes,” Karlsson says. “The biggest surprise was that it also translated into higher yields of our model proteins.”

The findings indicate that autophagy can serve as a target for host cell engineering alongside traditional methods of strengthening secretory machinery.

The study was authored by 15 researchers, with Karlsson serving as first author, and corresponding authors including Melanie Dannemeyer and Robert G. Roth from AstraZeneca alongside Rockberg.

Financial support for the project came from the Knut and Alice Wallenberg Foundation, AstraZeneca, and the Swedish innovation agency Vinnova through programs such as GeneNova, AAVNova, CellNova, and AdBIOPRO. Beyond drug manufacturing, researchers said that observations regarding protein turnover could interest studies of neurodegenerative conditions characterized by protein aggregation and impaired clearance.

Disabling cells cleanu
Photo: financialgazette.co.uk

Researchers disabled the ULK1 gene, which initiates autophagy, the cellular process responsible for breaking down and recycling proteins and organelles.

The study was conducted through a collaboration between researchers at KTH Royal Institute of Technology and industry scientists at AstraZeneca.

KTH Royal Institute of Technology, Sweden’s largest technical university, traces its origins to the Laboratorium Mechanicum founded in 1697 by Christopher Polhem. It was established as the Technological Institute in 1827 and received its current name in 1877. The university conducts research and education in engineering and technology across five schools with four campuses in and around Stockholm.

The findings appeared in the November 2026 issue of the peer-reviewed journal Cell Systems under the title “ULK1 knockout increases recombinant transcript abundance and improves recombinant membrane protein expression.”

About the author: Health Desk

Health Desk at Archynewsy.